secwatch.observer — SEC 8-K summary
======================================

Issuer:     CARGO Therapeutics, Inc. (—)
CIK:        0001966494
Form:       8-K
Filed at:   2025-01-29T23:59:59+00:00
Accession:  0001193125-25-015713
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.05
LLM model:  deepseek-v4-flash:cloud@v2

CARGO Therapeutics cuts workforce ~50%, ends firi-cel Phase 2 study
-------------------------------------------------------------------

- Workforce reduction of approximately 50% approved by board on Jan 28, 2025.
- Expected total charges of $31M-$37M: severance $4-5M, contract termination $20-22M, wind-down costs $7-10M; most in Q1 2025.
- Discontinues FIRCE-1 Phase 2 study of firicabtagene autoleucel (firi-cel).
- Will continue CRG-023 Phase 1 proof-of-concept and allogeneic platform; evaluating strategic options.
- Combined expense reductions expected to extend cash runway to mid-2028.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1966494/000119312525015713/0001193125-25-015713-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1966494/000119312525015713/d931594d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-015713

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer